Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptot...

Autores
Grossebrummel, Hannah; Peter, Tilmann; Mandelkow, Robert; Weiss, Martin; Muzzio, Damián Oscar; Zimmermann, Uwe; Walther, Reinhard; Jensen, Cristian Federico; Knabbe, Cornelius; Zygmunt, Marek; Burchardt, Martin; Stope, Matthias B.
Año de publicación
2015
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Abiraterone provides significant survival advantages in prostate cancer (PC), however, the current understanding of the molecular mechanisms of abiraterone is still limited. Therefore, the abiraterone impact on androgen receptor (AR)-positive LNCaP and AR-negative PC-3 cells was assessed by cellular and molecular analyses. The present study demonstrated, that abiraterone treatment significantly decreased cell growth, AR expression, and AR activity of AR-positive LNCaP cells. Notably, AR-negative PC-3 cells exhibited comparable reductions in cellular proliferation, associated with DNA fragmentation and pro-apoptotic modulation of p21, caspase-3, survivin, and transforming growth factor β (TGFβ). Our observations suggest that the attenuation of AR signaling is not the only rationale to explain the abiraterone anticancer activity. Abiraterone efficacy may play a more global role in PC progression control than originally hypothesized. In this regard, abiraterone is not only a promising drug for treatment of AR-negative PC stages, even more, abiraterone may represent an alternative for treatment of other malignancies besides prostate cancer.
Fil: Grossebrummel, Hannah. University Medicine Greifswald; Alemania
Fil: Peter, Tilmann. University Medicine Greifswald; Alemania
Fil: Mandelkow, Robert. University Medicine Greifswald; Alemania
Fil: Weiss, Martin. University Medicine Greifswald; Alemania
Fil: Muzzio, Damián Oscar. University Medicine Greifswald; Argentina
Fil: Zimmermann, Uwe. University Medicine Greifswald; Alemania
Fil: Walther, Reinhard. University Medicine Greifswald; Alemania
Fil: Jensen, Cristian Federico. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina. University Medicine Greifswald; Alemania
Fil: Knabbe, Cornelius. Ruhr-universität Bochum; Alemania
Fil: Zygmunt, Marek. University Medicine Greifswald; Alemania
Fil: Burchardt, Martin. University Medicine Greifswald; Alemania
Fil: Stope, Matthias B.. University Medicine Greifswald; Alemania
Materia
Prostate cancer
Abiraterone
Cytochrome P450 17S1
Apoptosis
Cell cycle
Transforming growth factor β
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/18119
Acceder
id CONICETDig_babe5ce2ac8692f86243baba1fa3d23e
oai_identifier_str oai:ri.conicet.gov.ar:11336/18119
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathwaysGrossebrummel, HannahPeter, TilmannMandelkow, RobertWeiss, MartinMuzzio, Damián OscarZimmermann, UweWalther, ReinhardJensen, Cristian FedericoKnabbe, CorneliusZygmunt, MarekBurchardt, MartinStope, Matthias B.Prostate cancerAbirateroneCytochrome P450 17S1ApoptosisCell cycleTransforming growth factor βhttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Abiraterone provides significant survival advantages in prostate cancer (PC), however, the current understanding of the molecular mechanisms of abiraterone is still limited. Therefore, the abiraterone impact on androgen receptor (AR)-positive LNCaP and AR-negative PC-3 cells was assessed by cellular and molecular analyses. The present study demonstrated, that abiraterone treatment significantly decreased cell growth, AR expression, and AR activity of AR-positive LNCaP cells. Notably, AR-negative PC-3 cells exhibited comparable reductions in cellular proliferation, associated with DNA fragmentation and pro-apoptotic modulation of p21, caspase-3, survivin, and transforming growth factor β (TGFβ). Our observations suggest that the attenuation of AR signaling is not the only rationale to explain the abiraterone anticancer activity. Abiraterone efficacy may play a more global role in PC progression control than originally hypothesized. In this regard, abiraterone is not only a promising drug for treatment of AR-negative PC stages, even more, abiraterone may represent an alternative for treatment of other malignancies besides prostate cancer.Fil: Grossebrummel, Hannah. University Medicine Greifswald; AlemaniaFil: Peter, Tilmann. University Medicine Greifswald; AlemaniaFil: Mandelkow, Robert. University Medicine Greifswald; AlemaniaFil: Weiss, Martin. University Medicine Greifswald; AlemaniaFil: Muzzio, Damián Oscar. University Medicine Greifswald; ArgentinaFil: Zimmermann, Uwe. University Medicine Greifswald; AlemaniaFil: Walther, Reinhard. University Medicine Greifswald; AlemaniaFil: Jensen, Cristian Federico. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina. University Medicine Greifswald; AlemaniaFil: Knabbe, Cornelius. Ruhr-universität Bochum; AlemaniaFil: Zygmunt, Marek. University Medicine Greifswald; AlemaniaFil: Burchardt, Martin. University Medicine Greifswald; AlemaniaFil: Stope, Matthias B.. University Medicine Greifswald; AlemaniaSpandidos Publ Ltd2015-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/18119Grossebrummel, Hannah; Peter, Tilmann; Mandelkow, Robert; Weiss, Martin; Muzzio, Damián Oscar; et al.; Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways; Spandidos Publ Ltd; International Journal Of Oncology; 48; 2; 11-20151019-64391791-2423CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.spandidos-publications.com/ijo/48/2/793info:eu-repo/semantics/altIdentifier/doi/10.3892/ijo.2015.3274info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:05:08Zoai:ri.conicet.gov.ar:11336/18119instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:05:08.829CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways
title Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways
spellingShingle Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways
Grossebrummel, Hannah
Prostate cancer
Abiraterone
Cytochrome P450 17S1
Apoptosis
Cell cycle
Transforming growth factor β
title_short Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways
title_full Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways
title_fullStr Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways
title_full_unstemmed Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways
title_sort Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways
dc.creator.none.fl_str_mv Grossebrummel, Hannah
Peter, Tilmann
Mandelkow, Robert
Weiss, Martin
Muzzio, Damián Oscar
Zimmermann, Uwe
Walther, Reinhard
Jensen, Cristian Federico
Knabbe, Cornelius
Zygmunt, Marek
Burchardt, Martin
Stope, Matthias B.
author Grossebrummel, Hannah
author_facet Grossebrummel, Hannah
Peter, Tilmann
Mandelkow, Robert
Weiss, Martin
Muzzio, Damián Oscar
Zimmermann, Uwe
Walther, Reinhard
Jensen, Cristian Federico
Knabbe, Cornelius
Zygmunt, Marek
Burchardt, Martin
Stope, Matthias B.
author_role author
author2 Peter, Tilmann
Mandelkow, Robert
Weiss, Martin
Muzzio, Damián Oscar
Zimmermann, Uwe
Walther, Reinhard
Jensen, Cristian Federico
Knabbe, Cornelius
Zygmunt, Marek
Burchardt, Martin
Stope, Matthias B.
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Prostate cancer
Abiraterone
Cytochrome P450 17S1
Apoptosis
Cell cycle
Transforming growth factor β
topic Prostate cancer
Abiraterone
Cytochrome P450 17S1
Apoptosis
Cell cycle
Transforming growth factor β
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv Abiraterone provides significant survival advantages in prostate cancer (PC), however, the current understanding of the molecular mechanisms of abiraterone is still limited. Therefore, the abiraterone impact on androgen receptor (AR)-positive LNCaP and AR-negative PC-3 cells was assessed by cellular and molecular analyses. The present study demonstrated, that abiraterone treatment significantly decreased cell growth, AR expression, and AR activity of AR-positive LNCaP cells. Notably, AR-negative PC-3 cells exhibited comparable reductions in cellular proliferation, associated with DNA fragmentation and pro-apoptotic modulation of p21, caspase-3, survivin, and transforming growth factor β (TGFβ). Our observations suggest that the attenuation of AR signaling is not the only rationale to explain the abiraterone anticancer activity. Abiraterone efficacy may play a more global role in PC progression control than originally hypothesized. In this regard, abiraterone is not only a promising drug for treatment of AR-negative PC stages, even more, abiraterone may represent an alternative for treatment of other malignancies besides prostate cancer.
Fil: Grossebrummel, Hannah. University Medicine Greifswald; Alemania
Fil: Peter, Tilmann. University Medicine Greifswald; Alemania
Fil: Mandelkow, Robert. University Medicine Greifswald; Alemania
Fil: Weiss, Martin. University Medicine Greifswald; Alemania
Fil: Muzzio, Damián Oscar. University Medicine Greifswald; Argentina
Fil: Zimmermann, Uwe. University Medicine Greifswald; Alemania
Fil: Walther, Reinhard. University Medicine Greifswald; Alemania
Fil: Jensen, Cristian Federico. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos. Universidad de Buenos Aires. Facultad de Medicina. Centro de Estudios Farmacológicos y Botánicos; Argentina. University Medicine Greifswald; Alemania
Fil: Knabbe, Cornelius. Ruhr-universität Bochum; Alemania
Fil: Zygmunt, Marek. University Medicine Greifswald; Alemania
Fil: Burchardt, Martin. University Medicine Greifswald; Alemania
Fil: Stope, Matthias B.. University Medicine Greifswald; Alemania
description Abiraterone provides significant survival advantages in prostate cancer (PC), however, the current understanding of the molecular mechanisms of abiraterone is still limited. Therefore, the abiraterone impact on androgen receptor (AR)-positive LNCaP and AR-negative PC-3 cells was assessed by cellular and molecular analyses. The present study demonstrated, that abiraterone treatment significantly decreased cell growth, AR expression, and AR activity of AR-positive LNCaP cells. Notably, AR-negative PC-3 cells exhibited comparable reductions in cellular proliferation, associated with DNA fragmentation and pro-apoptotic modulation of p21, caspase-3, survivin, and transforming growth factor β (TGFβ). Our observations suggest that the attenuation of AR signaling is not the only rationale to explain the abiraterone anticancer activity. Abiraterone efficacy may play a more global role in PC progression control than originally hypothesized. In this regard, abiraterone is not only a promising drug for treatment of AR-negative PC stages, even more, abiraterone may represent an alternative for treatment of other malignancies besides prostate cancer.
publishDate 2015
dc.date.none.fl_str_mv 2015-11
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/18119
Grossebrummel, Hannah; Peter, Tilmann; Mandelkow, Robert; Weiss, Martin; Muzzio, Damián Oscar; et al.; Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways; Spandidos Publ Ltd; International Journal Of Oncology; 48; 2; 11-2015
1019-6439
1791-2423
CONICET Digital
CONICET
url http://hdl.handle.net/11336/18119
identifier_str_mv Grossebrummel, Hannah; Peter, Tilmann; Mandelkow, Robert; Weiss, Martin; Muzzio, Damián Oscar; et al.; Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways; Spandidos Publ Ltd; International Journal Of Oncology; 48; 2; 11-2015
1019-6439
1791-2423
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.spandidos-publications.com/ijo/48/2/793
info:eu-repo/semantics/altIdentifier/doi/10.3892/ijo.2015.3274
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Spandidos Publ Ltd
publisher.none.fl_str_mv Spandidos Publ Ltd
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846781324173508608
score 12.982451

Publicaciones similares